Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
98%
COVID-19
91%
Infection
88%
Methicillin Resistant Staphylococcus Aureus
73%
Antibiotics
64%
Tazobactam
40%
Ceftolozane
40%
Pseudomonas aeruginosa
32%
Infective Endocarditis
29%
Blood Culture
29%
Cross Sectional Study
28%
Nasopharyngeal Swab
27%
Tertiary Care
27%
Carbapenem
26%
Antiinfective Agent
26%
Reverse Transcription Loop Mediated Isothermal Amplification
24%
Booster Dose
24%
Health Care Associated Pneumonia
24%
Favipiravir
24%
Fatality
24%
Internal Medicine
24%
Clinical Trial
24%
Infected Aneurysm
24%
Helicobacter Cinaedi
24%
Diagnostic Test
24%
Pulmonary Pathology
24%
Cefmetazole
24%
Escherichia coli
24%
Mucormycosis
24%
Antibiotic Therapy
24%
Time Series Analysis
24%
Periprosthetic Joint Infection
24%
Mycoplasma hominis
24%
Outpatient
24%
Human Coronavirus OC43
24%
Coronavirinae
24%
Meningitis
24%
Whole Genome Sequencing
24%
Aeromonas
24%
Pediatrics Patient
24%
Foot and Mouth Disease
24%
Reverse Transcription
24%
Long-Term Care
24%
Mixed Infection
24%
Pneumocystis Jirovecii
24%
Emergency Care
24%
Vaccine Hesitancy
24%
Embolism
24%
Immune Response
24%
Streptococcus Pneumoniae
24%
Odds Ratio
18%
Disease
18%
Antibiotic Resistance
16%
Skin Defect
14%
Carbapenemase
14%
Respiratory Failure
12%
Pneumococcal Infection
12%
Pathogen
12%
Diffuse Alveolar Damage
12%
Histopathology
12%
Cytopathogenic Effect
12%
Bronchopneumonia
12%
Clinical Feature
11%
Penicillinase
10%
Phylogeny
10%
Disease Epidemiology
9%
Methicillin Resistant Staphylococcus Aureus Infection
9%
Genome Sequencing
8%
Imipenem
8%
Garenoxacin
8%
Urogenital Tract Infection
8%
Septic Arthritis
8%
Host Susceptibility
8%
Sphingosine 1 Phosphate Receptor
8%
COVID-19 Vaccine
8%
Mycoplasma
8%
Avibactam Plus Ceftazidime
8%
Infection Prevention
8%
Omicron Coronavirus Variant
8%
Extended Spectrum Beta Lactamase
8%
Relebactam
8%
Symptom
7%
Logistic Regression Analysis
6%
Lactam
6%
Plasmid
6%
Epileptic Absence
6%
Reverse Transcription Polymerase Chain Reaction
6%
Breathing Rate
6%
Burn
6%
Species Invasion
6%
Integron
6%
Keyphrases
SARS-CoV-2 Infection
24%
Stewardship
24%
Infected Aortic Aneurysm
24%
Inpatient Facility
24%
Infected Aneurysm
24%
BA.1
24%
Intravascular Stenting
24%
Healthcare-associated Pneumonia
24%
Bacteremia
24%
Complete Genome Sequence
24%
National Survey in Japan
24%
Post-COVID-19
24%
BA.5
24%
Hospital Cluster
24%
Helicobacter Cinaedi
24%
Surgical Stent
24%
BA.2
24%
Admission Screening
24%
CA-MRSA
24%
Disseminated mucormycosis
24%
Periprosthetic Joint Infection
24%
Mycoplasma Hominis
24%
Mcr-9
24%
Multidrug-resistant Gram-negative Bacteria
24%
Fosfomycin Resistance
24%
Aeromonas Spp
24%
Anti-severe Acute Respiratory Syndrome Coronavirus 2 Antibody
24%
FosA
24%
A. Caviae
24%
Hydrophilia
24%
Phosphonoformate
24%
Concerted Reaction
24%
Depopulation
24%
Resistance Protein
24%
Foscarnet
24%
Stepwise mutation Model
24%
Threshold Phenomenon
24%
Initial Antibiotics
24%
Molecular Epidemiological Characteristics
24%
General Internal Medicine
24%
COVID-19 mRNA Vaccine
24%
Clostridium Butyricum
24%
Japan
24%
SARS-CoV-2 Antibodies
24%
BA.4
24%
Immunochromatography Test
24%
SARS-CoV-2 Pneumonia
24%
Program Vector
24%
Vector Autoregressive Model
24%
Cefcapene pivoxil
24%
Antibiotic Spectrum
24%
Off Periods
24%
USA300
24%
International Visitors
24%
NDM-5
24%
Prescribing Behavior
24%
BlaNDM-5
24%
Oxa1
24%
Catheter-related Bloodstream Infection (CRBSI)
20%
Nosocomial Cluster
16%
UhpT
16%
Audit-and-feedback
13%
Mucormycosis
12%
Seasonal Infection
12%
South Asian Countries
12%
Complex Class 1 Integron
12%
Genome Data
12%
Brain Heart Infusion
11%
Fosfomycin
10%
Escherichia Coli Bacteremia
9%
SSS-8
9%
Livestock Animals
8%
ST97
8%
Livestock-associated MRSA
8%
Medial Thigh
8%
Staphylococcus Aureus Bacteremia
8%
Furuncle
8%
Iliac Vein Thrombosis
8%
Practice Outcomes
8%
Preauthorization
8%
Treatment Guidance
8%
Antimicrobial Shortages
8%
Older Men Who Have Sex with Men
8%
Zone of Inhibition
8%
Multidrug-resistant E. Coli
8%
UhpA
8%
Parental Strain
8%
Garenoxacin
8%
Resistance Genotype
8%
Characteristic Resistance
8%
FosA3
8%
Aeromonas Species
8%
Mcr-3
8%
Hepatobiliary Complications
8%
Aeromonas Infection
8%
All Infections
8%
Enterobacter Cloacae
8%
Virology
8%
Asymptomatic Hypoglycemia
8%
Lack of Confidence
7%
Pharmacology, Toxicology and Pharmaceutical Science
Antibiotics
100%
Infection
93%
Antibiotic Agent
85%
Escherichia coli
75%
Penicillinase
69%
Symptom
52%
Bacteremia
51%
Cohort Study
49%
SARS Coronavirus
49%
Disease
47%
Ceftolozane
40%
Tazobactam
40%
Vaccination Policy
40%
Carbapenem
40%
Urinary Tract Infection
33%
Prevalence
31%
Pseudomonas aeruginosa
29%
Cross Sectional Study
28%
Catheter Infection
24%
Health Care Associated Pneumonia
24%
Favipiravir
24%
Cefmetazole
24%
Clinical Trial
24%
Fropenem
24%
Malignant Neoplasm
24%
Piperacillin Plus Tazobactam
24%
Carbapenem Derivative
24%
Cephalosporin
24%
Meropenem
24%
Escherichia Coli Pneumonia
24%
Coronavirinae
24%
Infectious Agent
24%
Fosfomycin
24%
Foot and Mouth Disease
24%
Foscarnet
24%
Solid Malignant Neoplasm
24%
Clostridium butyricum
24%
Probiotic Agent
24%
Klebsiella pneumoniae
24%
Cefcapene Pivoxil
24%
mRNA Vaccine
24%
Pneumocystis Jiroveci
24%
Cross-Sectional Study
20%
COVID-19 Vaccine
19%
Comorbidity
15%
Extended Spectrum Beta Lactamase
15%
Carbapenemase
14%
Observational Study
10%
Vaccine
9%
Community Acquired Pneumonia
9%
Lactam
8%
Antiinfective Agent
8%
Antimicrobial Resistance
8%
Garenoxacin
8%
Imipenem
8%
Relebactam
8%
Avibactam Plus Ceftazidime
8%
Case-Control Study
8%
Ceftriaxone
8%
Hospital Mortality
7%
Extended Spectrum Beta Lactamase Producing Escherichia Coli
7%
Multiple Chronic Conditions
6%
Epileptic Absence
6%
Virus Infection
6%
Cefazolin
6%
Adverse Outcome
6%
Ureaplasma
6%
Recurrent Disease
5%
Aerobactin
5%